Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Sirolimus for Nosebleeds in HHT
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT05269849
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
The Role of Sirolimus in Preventing Functional Decline in Older Adults
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Irina Timofte
- Target Recruit Count
- 10
- Registration Number
- NCT05237687
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
mTOR as Mediator of Insulin Sensitivity Study
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 10
- Registration Number
- NCT05233722
- Locations
- 🇩🇰
University of Copenhagen, Copenhagen, Denmark
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 206
- Registration Number
- NCT05193565
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul, Korea, Republic of
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Darcy Krueger
- Target Recruit Count
- 64
- Registration Number
- NCT05104983
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Katarzyna Kotulska
- Target Recruit Count
- 60
- Registration Number
- NCT04987463
- Locations
- 🇵🇱
Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, Poland
🇵🇱Medical University of Warsaw, Department of Pediatric Neurology, Warsaw, Poland
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT04959175
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT04948203
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04892212
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.